Quivivepharma inc

10:45 AM - 11:00 AM (EDT), Tuesday, June 6, 2023 ・ Session Room 104B
No new mechanism to treat pain has been developed in the last 30 years. We must treat pain; a basic human right.

90% of opioids prescribed are generic short acting opioids. Treatment of acute pain with these generic opioids means unopposed respiratory depression or development of opioid use disorder (OUD).

Quivivepharma is making these opioids better. Quivivepharma has combined generic opioids with a respiratory stimulant to prevent opioid induced respiratory depression, deter abuse, and save lives.ed to make the opioids we have now better.

Quivive is on a 505(b)(2) pathway for approval, has 2 granted patents, and has filed a FDA initial new drug application (IND). We are supported by initial seed investors and a 2 year $1.9 million NIDA/NIH grant for first in human studies at the Cleveland Clinic.

Our team is supported by experts in clinical medicine, regulatory affairs, and drug development with over 200 years of experience.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Pain Management
Lead Product in Development:
Hydrocodone + respiratory stimulant and Oxycodone + respiratory stimulant
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):